Join us on 12-15-2022 for a live seminar about RNA SEQ
Join us on 12-15-2022 for a live seminar about RNA SEQ
Our Discovery Services augment your own expertise or give you capacity when you need it. Our team of leading scientists runs bespoke drug discovery campaigns for our partners and is continually innovating to validate and utilize cutting edge technology in our discovery offerings.
We started with the ATX-Gx transgenic humanized mice platform for antibody discovery and have built a robust discovery services organization around that foundational technology, while constantly improving our capabilities to help our partners find the ideal antibodies for therapeutic intent.
There are many ways to discover an antibody, but not all antibodies are created equal. We offer a precision approach to generating, retrieving, and assessing antibodies with the specific properties required for the intended therapeutic effect.
We are continuously innovating to create new platform technology and capabilities, which are first made available through campaigns with Alloy Antibody Discovery Services. The ATX-CLC is a transgenic murine in vivo discovery platform, optimized for bispecific and multispecific human antibody-based therapeutics.
We develop, improve, license, and share foundational, pre-competitive antibody discovery platforms for use in your lab, with your preferred CRO, or with our platform experts in Alloy Discovery Services. We have designed our licenses with flexible, affordable terms that allow our partners to easily access all our continuous platform improvements.
ATX-Gx™ is the world’s most popular humanized mice platform for antibody discovery, available through Alloy Antibody Discovery Services or in your lab in as little as two weeks.
We accelerate partner programs by providing early insights into functional activity of therapeutic candidates generated from Alloy discovery programs across all modalities. Generally, we offer these services in line with DeepImmune for human antibody discovery and Keyway for therapeutic TCR discovery, but we can offer advice and services on a case-by-case basis for our license partners and ecosystem collaborators.
Our first platform, the ATX-Gx™, is the world’s fastest growing transgenic mouse platform for human monoclonal antibody discovery. Partners may ship mice to their labs, work with an ATX-Gx certified service provide, or engage with our flagship antibody discovery service, DeepImmune.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industrys standard dummy text ever since the 1500s.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industrys standard dummy text ever since the 1500s.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industrys standard dummy text ever since the 1500s.
Learn more about licensing our platforms for use your lab or starting a campaign with DeepImmune.
We’ve built a robust unique Deep Learning and sequencing engine that characterizes immune repertoire data, rapidly identifies novel binders, and optimizes candidates by scanning the breadth of sequence variants.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industrys standard dummy text ever since the 1500s.
We are also active in genetic medicines, peptides, cell therapy, and drug delivery technology through new Venture Studio companies, discovery services, and internal innovation projects.
TCRS
Learn more about our work in these areas.
Get unlimited access to all our current and future technology for one fixed annual fee, with no Alloy milestones or royalties.
We have new innovations under development across all six of our modalities. These are all available for co-development with partners of all types. As an Alloy platform development partner, you’ll access the resulting platform royalty-free, in perpetuity.
Explore:
Our research facilities:
Boston, MA
Cambridge, UK
Basel, CH
Athens, GA
© 2023 Alloy Therapeutics, Inc. All Rights Reserved.
Thanks for your interest in our white paper, Targeting GPCRs with DeepImmune Antibody Discovery.
G protein-coupled receptors (GPCRs) play a central role in multiple physiological functions, from endocrine sensing to neurotransmission to chemotaxis of immune cells. This class has long been an attractive target for novel antibody drug discovery campaigns in multiple disease indications, but their unique nature produces many challenges for in vivo antibody discovery. In this white paper, we detail how our humanized mouse discovery platform, the ATX-Gx™, have been successfully utilized for GPCR-targeted antibody discovery, Alloy Antibody Discovery’s DeepImmune™ module builds on this robust in vivo discovery platform, coupling best-in-class immunogen production with multiple binder recovery approaches, and advanced machine-learning-based techniques for lead identification and optimization.
I’d like more material about Keyway TCR Discovery
Thanks for your interest in our recent Keyway TCRm Discovery webinar, Increasing Target Specificity and Tackling Intracellular Targets for TCRm Therapeutics Development with Keyway’s TCRm Discovery Offering. In it, the team at the helm of our TCR mimic discovery campaigns shared:
1. An overview of common challenges to intracellular protein-targeting drug discovery
2. Keyway’s industry-leading solutions to TCRm/TCR-based therapeutic discovery including its proprietary specificity screening and high-quality pMHC complex antigen production capabilities
3. A case study featuring the discovery of a panel of highly specific, functional TCRm binders against an intracellular immuno-oncology target
Upon filling out this form, you will receive an email with a link to the webinar recording.
